BioStem Technologies, Inc. - 8-K Filing

BioStem Technologies reports Q3 2026 net revenue of $7.6 million and raises full-year 2026 revenue guidance to $28M–$29M. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $BSEM

Read the full article at SEC EDGAR

More Regulatory news